Abstract: Disclosed is a cosmetic composition comprising film-forming polymer having a contact angle of at least 85°, wax, optical particle, and at least 20% of water by weight of the composition.

Abstract: Disclosed is the use of the compounds (A) corresponding to formula wherein R1 represents C6-C24alkyl; R2 is hydrogen; or C1-C4alkyl; R3 is a radical of formula (1a) *—(CH2)n1—R4 R4 is a heterocyclic or aromatic radical comprising 4 to 6 carbon atoms which can contain from 1 to 3 nitrogen and/or oxygen atoms; n1 is a number from 0 to 5; or R2 and R3 together with the linking nitrogen atom form a heterocyclic radical comprising 4 to 6 carbon atoms which can contain one or more oxygen or nitrogen atoms; as solubilizing agent for organic UV filters (B) selected from (B1) benzophenone derivatives, (B2) hydroxyphenyl triazine derivatives; and (B3) trianilino-s-triazine derivatives.

Abstract: The invention concerns a storage stable pharmaceutical preparation comprising oxycodone and naloxone for use in pain therapy, with the active compounds being released from the preparation in a sustained, invariant and independent manner.

Abstract: Provided herein are micellic assemblies comprising a plurality of copolymers. In certain instauces, micellic assemblies provided herein are pH sensitive particles.

Abstract: Lecithin based microemulsion and their uses as nanoreactors and carrying materials are disclosed. In one embodiment, a method of forming a nanomaterial comprises mixing a lecithin based microemulsion with a first reactant and a second reactant. In a further embodiment, a method for encapsulating a nanomaterial in a lecithin based microemulsion forming a composition and wherein the composition forms a dispersion in an aqueous solution, polar solution, or a non-polar solution.

Abstract: Zinc oxide coated with silicon oxide of the present invention is zinc oxide which is coated with silicon oxide wherein surfaces of zinc oxide particles are coated with silicon oxide coatings, and the coated zinc oxide particles comprises at least one element selected from a group consisting of Mg, Ca, and Ba.

Abstract: This invention is directed to aragonite and calcite hydrogel biomatrices, optionally seeded with precursor cells and uses thereof in tissue engineering, regeneration and repair, including in inducing or enhancing bone formation, cartilage formation or a combination thereof in a subject, and kits related thereto.

Abstract: Disclosed are a dry bonding system and a wearable device for skin bonding including the dry bonding system.

Abstract: The present invention is directed toward fatty acid-based particles, and methods of making such particles. The particles can be associated with an additional, therapeutic agent. Also provided herein is a method of forming fatty acid particles, comprising associating a cross-linked, fatty acid-derived biomaterial with a cryogenic liquid; and fragmenting the bio material/cryogenic liquid composition, such that fatty acid particles are formed. The particles can be used for a variety of therapeutic applications.

Abstract: Provided are a silicon oxide-coated zinc oxide, a method for producing the same, a composition and a cosmetic including a silicon oxide-coated zinc oxide. The silicon oxide-coated zinc oxide is a silicon oxide-coated zinc oxide formed by coating surfaces of zinc oxide particles with a silicon oxide coat, in which an average particle diameter of the zinc oxide particles is in a range of more than 50 nm and 500 nm or less, and, when an abundance ratio of silicon in the silicon oxide coat in a Q3 environment is indicated by Q3, and an abundance ratio in a Q4 environment is indicated by Q4, Q3+Q4?0.6 and Q4/(Q3+Q4)?0.5 are satisfied.

Abstract: An aqueous oral liquid pharmaceutical composition system with reduced propensity for agglomeration and phase separation which is particularly amendable to the suspension of one or more pharmaceutical actives that are substantially insoluble in water. The oral liquid pharmaceutical composition may further comprise pharmaceutical actives that are soluble in water and dissolve in the aqueous medium. In the composition of the invention both suspended and any dissolved active agents are distributed homogeneously.

Abstract: The present invention relates to a biomaterial, specifically a hydrogel, based on the extracellular matrix of the umbilical cord for its application in regenerative medicine. The invention particularly relates to a biomaterial made up of glycosaminoglycans present exclusively in the Wharton's jelly of the umbilical cord (which can optionally be combined with cells as a combination therapy), and also to the methods for the production and use thereof.

Abstract: A defoaming adjuvant comprises a solid particulate carrier and a polyalkylene glycol adsorbed on to the solid particulate carrier, where the polyalkylene glycol is a reaction product of an alkyl alcohol initiator with 1, 2-butylene oxide and, optionally, propylene oxide.

Abstract: The present invention provides a solid powder cosmetic exhibiting excellent ease of loosening of the cosmetic, smooth feeling in use, and adhesiveness to the skin and also exhibiting no change in usability in continuous use and having excellent filling and molding properties and drop strength. The invention relates to a solid powder cosmetic containing following components (A), components (B), and components (C); (A) a powder, (B) a (sodium acrylate/sodium acryloyldimethyl taurate) copolymer, and (C) a water-swelling clay mineral.

Abstract: A coating for an expandable portion of a catheter comprising a hydrophobic matrix and a dispersed phase is disclosed. The dispersed phase comprises a plurality of micro-reservoirs dispersed in the hydrophobic matrix, wherein the plurality of micro-reservoirs comprises a first active agent and a first biodegradable or bioerodable polymer. A coating formulation and a method for forming the coating are also disclosed. A catheter comprising the coating on the expandable portion and a method for treating a condition are also provided.

Abstract: The present invention provides a method of treating constipation and compositions useful in said method. The method comprises administering to a subject in need thereof an effective amount of a crosslinked carboxymethylcellulose having high elastic modulus coupled with high absorbance capacity when swollen in simulated gastric fluid/water (1:8) and simulated intestinal fluids.

Abstract: Effective Photodynamic therapy (PDT) against C. difficile is provided using a composition including chitosan and tetracycline.

Abstract: Disclosed are formulations and related methods that comprise a non-polymeric, non-water soluble high viscosity liquid carrier material having a viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; a specified linear polymer comprising lactide repeat units; and one or more solvents that have a solvent capacity.

Abstract: This invention provides for biocompatible, biodegradable eye drop pharmaceutical formulations useful for the treatment of ocular indications. In particular, tocopherols and their esters of low water solubility, notably ?-tocopheryl acetate, are exceptional vehicles for biocompatible, nonirritating topical eye drop formulations that provide sustained release of active agents.

Abstract: In accordance with one aspect of the invention, injectable compositions are provided, which contain temperature-sensitive hydrogel particles. The hydrogel particles may be provided in dry form, or they may be provided in hydrated form in an aqueous fluid. The temperature-sensitive hydrogel particles may have an upper critical solution temperature (UCST) below normal body temperature, they may have a lower critical solution temperature (LCST) above normal body temperature, or they may have a LCST that changes from below normal body temperature to above normal body temperature after injection into a subject.